Chapman Tripp is advising New Zealand healthcare company EBOS Group Ltd. on its proposed $859.8 million purchase of Australian pharmaceuticals wholesaler Symbion Ltd.

EBOS is buying Symbion from The Zuellig Group Inc., a Hong Kong-based investment company, for $679.3 million plus $180.5 million in assumed debt. The transaction is being funded through a combination of cash and the issue of new EBOS shares to Zuellig. After the issue, Zuellig will be a 40 percent shareholder in the enlarged EBOS Group.

The deal, subject to shareholder approval, is expected to close this month.

Chapman Tripp Christchurch partner Alister McDonald is acting for EBOS.

Corrs Chambers Westgarth Melbourne partner Justin Fox is representing Symbion on the transaction.